NCT02956642: SUGAR

Study to Understand Gaining Access to Blood Glucose Records

Completed NA Results posted Last updated 30 April 2025

What this trial tests

NA trial testing Livongo Health System in Diabetes Mellitus in 84 participants. Completed in 17 January 2021.

Timeline

14 November 2018

Primary endpoint
17 January 2021

17 January 2021

Quick facts

Lead sponsor	University of California, San Francisco
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	84
Start date	14 November 2018
Primary completion	17 January 2021
Estimated completion	17 January 2021
Sites	1 location across United States

Drugs / interventions tested

• Livongo Health System
• iHealth Glucose Meter

Conditions studied

• Diabetes Mellitus — all drugs for Diabetes Mellitus →

Sponsor

University of California, San Francisco

Who can join

18 and older, any sex, with Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Mean HbA1c Levels Primary · 6 months

Three HbA1c measures per study participant will be acquired at 3 points in the study duration (baseline, 3 months, and 6 months). In order to compare the changes in HbA1c, the values may be analyzed and separated with regard to duration of diabetes (days, months, years), and/or HbA1c levels at baseline. Reported in this table are the means for all participants for each given timepoint.

Baseline

Group	Value	95% CI
Blood Glucose Monitoring System	8.0	± 1.5
Standard Blood Glucose Monitoring	7.3	± 1.1

3 months

Group	Value	95% CI
Blood Glucose Monitoring System	7.9	± 1.5
Standard Blood Glucose Monitoring	7.6	± 1.2

6 months

Group	Value	95% CI
Blood Glucose Monitoring System	7.9	± 1.1
Standard Blood Glucose Monitoring	7.5	± 1.1

Change in HbA1c Primary · 6 months

In this analysis, change in HbA1c within individual participants was compared from baseline to 6 months. Only participants with 6-month data were included.

Group	Value	95% CI
Blood Glucose Monitoring System	0.31	± 0.79
Standard Blood Glucose Monitoring	0.38	± 0.83

Mean Fasting LDL Secondary · 6 months

As a secondary outcome, we will determine the effect of use of the Livongo Health system on fasting lipid panels (LDL). A lipid panel will be done at baseline, 3 months, and at 6 months. Reported in this table are means for all participants with data at each timepoint.

Baseline

Group	Value	95% CI
Blood Glucose Monitoring System	81	± 33.5
Standard Blood Glucose Monitoring	94.5	± 26.7

3 months

Group	Value	95% CI
Blood Glucose Monitoring System	73.9	± 32
Standard Blood Glucose Monitoring	98.2	± 51.7

6 months

Group	Value	95% CI
Blood Glucose Monitoring System	87.9	± 32.9
Standard Blood Glucose Monitoring	92.7	± 48.8

Change in Fasting LDL Secondary · 6 months

In this analysis, change in fasting LDL within individual participants was compared from baseline to 6 months. Only participants with 6-month data were included.

Group	Value	95% CI
Blood Glucose Monitoring System	-0.3	± 24.7
Standard Blood Glucose Monitoring	-25.25	± 35.7

Sponsor's own description

This study is a two-arm randomized controlled trial in which participants will receive either the Livongo Health system or iHealth glucose meter for measuring their blood glucose. The study hypothesizes the use of the Livongo Health system results in a greater improvement in A1c compared to standard blood glucose monitoring, as demonstrated by the iHealth Bluetooth-enabled glucose meter.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.